LungFX device
Lung Bioengineering, Inc. · Decision date Jun 22, 2026
What did the FDA approve?
FDA records P240033 as an original PMA application. The recorded decision is approval, dated Jun 22, 2026.
FDA approval order statement
This device (LungFX) is indicated for centralized, ex vivo (outside the body) evaluation of deceased-donor lungs (single and double) that cannot be placed for transplantation by an Organ Procurement Organization (OPO) with any of the matched candidates if using direct-to-recipient procurement and preservation procedures. LungFX provides normothermic perfusion and ventilation of procured donor lungs initially stored with cold static preservation solution.LungFX is intended to allow for re-assessment, in a controlled environment, of procured donor lungs suitability for transplantation into male and female patients aged 18 years or older with end-stage lung disease awaiting first time (double or single) lung transplantation. Lungs accepted for transplantation after LungFX require a second period of storage with cold static preservation solution, and cumulative preservation time of transplanted lungs is not intended to exceed 20 hours.
- Regulatory pathway
- Original PMA
- Clinical specialty
- Gastroenterology, Urology
- Decision date
- Jun 22, 2026
Regulatory record facts
- Identifier
- P240033
- Regulatory pathway
- Premarket approval application
- Applicant
- Lung Bioengineering, Inc.
- Product code
- PHO
- Decision code
- APPR
- Decision date
- Jun 22, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Normothermic preservation system for transplantation of initially unacceptable donor lungs.
- Applicant
- Lung Bioengineering, Inc.
- Product code
- PHO
- FDA device class
- 3
The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.
FDA decision timeline
P240033 received
Application receipt date recorded by FDA.
P240033 · FDA decision
APPR
P240033/S001 · Related supplement
LungFX Device
P240033/S002 · Related supplement
LungFX Device
Timeline entries are records held by MedtechLedger for P240033. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P240033
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
LungFX DeviceP240033/S001 | Lung Bioengineering, Inc. | PMA supplement | Oct 16, 2026 | FDA |
LungFX DeviceP240033/S002 | Lung Bioengineering, Inc. | PMA supplement | Oct 16, 2026 | FDA |
Explore the linked device profile
Other records with product code PHO
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Traferox Technologies, Inc. | PMA supplement | Oct 30, 2026 | FDA | |
| Traferox Technologies, Inc. | PMA supplement | Oct 30, 2026 | FDA | |
XPS with Steen Solution PerfusateP180014/S014 | Xvivo Perfusion, Inc. | PMA supplement | Sep 16, 2026 | FDA |
TorEx Lung Perfusion SystemP250025 | Traferox Technologies, Inc. | PMA approval | Jul 15, 2026 | FDA |
| Xvivo Perfusion, Inc. | PMA approval | Apr 26, 2019 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Lung Bioengineering, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Lb1 Bldg., 1015 Spring St., Silver Spring, MD, 20910
Sources and methodology
- Original FDA record: P240033
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records





